Anand Vijayakumar Palur Ramakrishnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anand Vijayakumar Palur Ramakrishnan has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Amol Achyutrao Raje
Drug Metabolism and Pharmacokinetics, Discovery Biology, Syngene International Limited, Bengaluru, 560099, India
2 shared publications - Saivishal Daripelli
Drug Metabolism and Pharmacokinetics, Discovery Biology, Syngene International Limited, Bengaluru, 560099, India
2 shared publications - Treesa P. Varghese
Department of Pharmacy Practice, Yenepoya Pharmacy College and Research Centre, Yenepoya (Deemed to Be University), Mangalore, India
2 shared publications - Vishwottam Kandikere
Drug Metabolism and Pharmacokinetics, Discovery Biology, Syngene International Limited, Bengaluru, 560099, India
2 shared publications Aditya Prakash Jha
JSS College of Pharmacy Ooty
1 shared publicationAman Khandelwal
JSS College of Pharmacy Ooty
1 shared publication
Latest Publications
- 6 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Inflammation & Allergy Drug Discovery
- Vol. 20, 1-10
Synovial Microdialysis for Evaluating Methotrexate Disposition in Male Sprague-dawley Rats: A Translational Approach to Anti-rheumatoid Drug Discovery
Introduction: The efficacy of Rheumatoid Arthritis (RA) treatment depends on adequate drug exposure within the joint; however, intra-articular pharmacokinetics remain poorly understood. Synovial microdialysis enables continuous measurement of unbound drug concentrations in joints. This study aimed to evaluate the applicability of techniques like microdialysis and lavage collection as preclinical tools for measuring unbound intra-articular drug exposure by characterizing methotrexate (MTX) pharmacokinetics in rats. Methods: In this study, male Sprague-Dawley (SD) rats were used for evaluating the kinetics of MTX. A linear probe was implanted in the knee joint of anesthetized rats to perform synovial microdialysis. An intravenous dose of 1 and 3 mg/kg was administered for synovial microdialysis, while lavage was performed in a parallel group at 3 mg/kg for comparison. Plasma protein binding was determined using the equilibrium dialysis method. Pharmacokinetic parameters were derived using non-compartmental analysis, and inter-method agreement was evaluated. Results: MTX showed moderate plasma protein binding (~51% unbound) and dose-proportional systemic exposure at tested doses. Microdialysis data revealed rapid joint penetration (Tmax ≈ 0.25 h) and synovial half-life comparable to unbound plasma kinetics. At 3 mg/kg, microdialysis and lavage demonstrated close agreement (2.9% difference, ~2% CV), with microdialysis yielding slightly higher concentrations, likely due to its ability to measure unbound drug without dilution bias. Discussion: The strong concordance between microdialysis and lavage confirms both methods capture intra-articular MTX exposure. However, microdialysis offers superior physiological relevance by continuously quantifying unbound drug without dilutional artifacts. The alignment of synovial and plasma half-life supports rapid equilibration between systemic and joint compartments, reinforcing its utility for mechanistic and PK-PD studies. Conclusion: Synovial microdialysis provides a robust and physiologically relevant approach for quantifying active drug exposure in the joint and offers clear advantages over synovial lavage for preclinical evaluation of anti-rheumatic therapies.
- 6 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Inflammation & Allergy Drug Discovery
- Vol. 20, 1-10
Synovial Microdialysis for Evaluating Methotrexate Disposition in Male Sprague-dawley Rats: A Translational Approach to Anti-rheumatoid Drug Discovery
Introduction: The efficacy of Rheumatoid Arthritis (RA) treatment depends on adequate drug exposure within the joint; however, intra-articular pharmacokinetics remain poorly understood. Synovial microdialysis enables continuous measurement of unbound drug concentrations in joints. This study aimed to evaluate the applicability of techniques like microdialysis and lavage collection as preclinical tools for measuring unbound intra-articular drug exposure by characterizing methotrexate (MTX) pharmacokinetics in rats. Methods: In this study, male Sprague-Dawley (SD) rats were used for evaluating the kinetics of MTX. A linear probe was implanted in the knee joint of anesthetized rats to perform synovial microdialysis. An intravenous dose of 1 and 3 mg/kg was administered for synovial microdialysis, while lavage was performed in a parallel group at 3 mg/kg for comparison. Plasma protein binding was determined using the equilibrium dialysis method. Pharmacokinetic parameters were derived using non-compartmental analysis, and inter-method agreement was evaluated. Results: MTX showed moderate plasma protein binding (~51% unbound) and dose-proportional systemic exposure at tested doses. Microdialysis data revealed rapid joint penetration (Tmax ≈ 0.25 h) and synovial half-life comparable to unbound plasma kinetics. At 3 mg/kg, microdialysis and lavage demonstrated close agreement (2.9% difference, ~2% CV), with microdialysis yielding slightly higher concentrations, likely due to its ability to measure unbound drug without dilution bias. Discussion: The strong concordance between microdialysis and lavage confirms both methods capture intra-articular MTX exposure. However, microdialysis offers superior physiological relevance by continuously quantifying unbound drug without dilutional artifacts. The alignment of synovial and plasma half-life supports rapid equilibration between systemic and joint compartments, reinforcing its utility for mechanistic and PK-PD studies. Conclusion: Synovial microdialysis provides a robust and physiologically relevant approach for quantifying active drug exposure in the joint and offers clear advantages over synovial lavage for preclinical evaluation of anti-rheumatic therapies.
- 6 May 2026
- Published by Bentham Science Publishers Ltd. in Clinical Cancer Drugs
- Vol. 12 (1) , 1-14
Dostarlimab in the Treatment of Endometrial Cancer: An Overview
Introduction: Endometrial cancer, the most frequent gynaecological malignancy in developed countries, is rising and has few modern therapies. Dostarlimab may treat MMRdeficient (dMMR) and MSI-H tumours. Methods: GARNET and RUBY clinical trial data were evaluated for ORR, PFS, and safety. Also, pembrolizumab and other immunotherapeutics were compared. Results: Dostarlimab inhibits PD-1, activating T cells and anti-tumour immunity. RUBY observed increased tiredness, diarrhoea, and nausea, and improved PFS in dMMR/MSI-H endometrial cancer patients, whereas GARNET reported a 43.5% ORR. Dostarlimab works as well as pembrolizumab for certain patients. Biomarker-driven immunotherapy has potential for CRC and NSCLC. Discussion: Here, dostarlimab's promising PD-1 inhibitor efficacy in endometrial cancer therapy with dMMR/MSI-H tumours is reviewed. Immunogenic tumours activate T-cells via PD-1 targeting. In dMMR/MSI-H patients, GARNET showed a 43.5% objective response rate, whereas RUBY improved progression-free survival with dostarlimab and chemotherapy. Dostarlimab and PD-1 inhibitors induce tiredness, diarrhoea, and nausea. Treatment may be isolated or combined for long-term therapy. Studies suggest that dostarlimab outperforms pembrolizumab. Though encouraging, larger populations and additional tumour types require further investigation. A successful dostarlimab study requires biomarkers and randomized controlled trials. Conclusion: Dostarlimab is a highly effective immunotherapeutic option for endometrial cancer, particularly in dMMR/MSI-H cases. Its favourable efficacy and safety profile make it a key agent in personalized cancer treatment, with ongoing trials expanding its clinical applications.
- 6 May 2026
- Published by Bentham Science Publishers Ltd. in Clinical Cancer Drugs
- Vol. 12 (1) , 1-14
Dostarlimab in the Treatment of Endometrial Cancer: An Overview
Introduction: Endometrial cancer, the most frequent gynaecological malignancy in developed countries, is rising and has few modern therapies. Dostarlimab may treat MMRdeficient (dMMR) and MSI-H tumours. Methods: GARNET and RUBY clinical trial data were evaluated for ORR, PFS, and safety. Also, pembrolizumab and other immunotherapeutics were compared. Results: Dostarlimab inhibits PD-1, activating T cells and anti-tumour immunity. RUBY observed increased tiredness, diarrhoea, and nausea, and improved PFS in dMMR/MSI-H endometrial cancer patients, whereas GARNET reported a 43.5% ORR. Dostarlimab works as well as pembrolizumab for certain patients. Biomarker-driven immunotherapy has potential for CRC and NSCLC. Discussion: Here, dostarlimab's promising PD-1 inhibitor efficacy in endometrial cancer therapy with dMMR/MSI-H tumours is reviewed. Immunogenic tumours activate T-cells via PD-1 targeting. In dMMR/MSI-H patients, GARNET showed a 43.5% objective response rate, whereas RUBY improved progression-free survival with dostarlimab and chemotherapy. Dostarlimab and PD-1 inhibitors induce tiredness, diarrhoea, and nausea. Treatment may be isolated or combined for long-term therapy. Studies suggest that dostarlimab outperforms pembrolizumab. Though encouraging, larger populations and additional tumour types require further investigation. A successful dostarlimab study requires biomarkers and randomized controlled trials. Conclusion: Dostarlimab is a highly effective immunotherapeutic option for endometrial cancer, particularly in dMMR/MSI-H cases. Its favourable efficacy and safety profile make it a key agent in personalized cancer treatment, with ongoing trials expanding its clinical applications.
- 27 March 2026
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 335 (4) , 3331-3341
The role of radiopharmaceuticals in biomedical science and clinical practice: from diagnostic imaging to targeted therapy
- 27 March 2026
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 335 (4) , 3331-3341
The role of radiopharmaceuticals in biomedical science and clinical practice: from diagnostic imaging to targeted therapy
- 16 March 2026
- Published by Taylor & Francis in Xenobiotica
- Vol. 56 (3) , 204-213
Model-based steady state pharmacokinetic predictions using high throughput cassette infusion approach in mice
- 16 March 2026
- Published by Taylor & Francis in Xenobiotica
- Vol. 56 (3) , 204-213
Model-based steady state pharmacokinetic predictions using high throughput cassette infusion approach in mice
- Open Access
- 6 March 2026
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 22 (10) , 1-14
“Synergistic Potential of Linagliptin and Resveratrol in Mitigating Type-II Diabetes-Induced Nephropathy”: A Comprehensive Review
This narrative review aims to elucidate the significance of the synergistic effects of linagliptin and resveratrol and also explores their individual mechanisms of action in diabetic complications such as nephropathy. A systematic literature analysis examined the synergistic potential of resveratrol and linagliptin in diabetic nephropathy. A critical review of their antioxidant, anti-inflammatory, and anti-fibrotic mechanisms was conducted. Various studies revealed that linagliptin improves renal outcomes through both incretin-dependent and independent pathways, reducing oxidative stress, inflammation, and AGE-RAGE axis activation. It also exhibits the capacity to reduce albuminuria and renal fibrosis in diabetic animal models. Resveratrol similarly demonstrates substantial renoprotective benefits through activation of the AMPK/Nrf2 pathway, mitigating oxidative stress and downregulating inflammatory markers such as tumor necrosis factor-alpha and interleukin-1 beta. The synergistic use of linagliptin and resveratrol may provide greater benefits than their individual effects, including improved glycaemic control, reduced renal oxidative stress, and decreased inflammatory and fibrotic markers, thereby offering superior protection against diabetic nephropathy.
- 6 March 2026
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 22 (10) , 1-14
Open Access“Synergistic Potential of Linagliptin and Resveratrol in Mitigating Type-II Diabetes-Induced Nephropathy”: A Comprehensive Review
This narrative review aims to elucidate the significance of the synergistic effects of linagliptin and resveratrol and also explores their individual mechanisms of action in diabetic complications such as nephropathy. A systematic literature analysis examined the synergistic potential of resveratrol and linagliptin in diabetic nephropathy. A critical review of their antioxidant, anti-inflammatory, and anti-fibrotic mechanisms was conducted. Various studies revealed that linagliptin improves renal outcomes through both incretin-dependent and independent pathways, reducing oxidative stress, inflammation, and AGE-RAGE axis activation. It also exhibits the capacity to reduce albuminuria and renal fibrosis in diabetic animal models. Resveratrol similarly demonstrates substantial renoprotective benefits through activation of the AMPK/Nrf2 pathway, mitigating oxidative stress and downregulating inflammatory markers such as tumor necrosis factor-alpha and interleukin-1 beta. The synergistic use of linagliptin and resveratrol may provide greater benefits than their individual effects, including improved glycaemic control, reduced renal oxidative stress, and decreased inflammatory and fibrotic markers, thereby offering superior protection against diabetic nephropathy.
- 1 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (5) , 7569-7582
Exploring molecular frameworks for modulating NLRP3-driven neuroinflammation in Alzheimer’s disease
- 1 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (5) , 7569-7582
Exploring molecular frameworks for modulating NLRP3-driven neuroinflammation in Alzheimer’s disease
- Open Access
- 20 November 2023
- Published by Wiley
FUTURE PROGNOSIS FOR CARDIOVASCULAR COMPLICATIONS ASSOCIATED WITH SARS-COV-2: A PHARMACOLOGICAL AND MOLECULAR PERSPECTIVE
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the coronavirus disease 2019 (COVID-19), which is associated with cardiovascular problems and serious lung damage. COVID-19 patients with comorbid conditions are at a significantly elevated risk of increased morbidity and mortality. Angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) are the two key host contributing factors for the severity and pathogenesis of COVID-19. The principal SARS-CoV-2 entrance receptor, ACE2, is expressed equally in most organs and produces cardio-protective vasodilators by physically degrading angiotensin II, the main controller of the Renin-Angiotensin Aldosterone System. However, treatment for cardiovascular disease (CVD) commonly involves RAAS inhibitors, which may increase ACE2 expression. Objective: To summarize the pharmacological molecular discoveries into the processes of viral infection and its consequences for cardiovascular disease and to offer suggestions for the practical management and treatment of COVID-19-related cardiovascular injury. Methods: This review focuses on the important considerations related to the cardiovascular manifestations of COVID-19 and discusses the various mechanisms of COVID-19 that contribute to its molecular and pharmacological presentation of cardiovascular injury. Results: The host-pathogen relationship began with ACE2’s attachment to the S-protein and proceeded with TMPRSS2’s proteolytic cleavage of the viral spike (S)-protein and ACE2. Currently discovered protein-protein interactions explain the uniqueness of SARS-CoV-2 infection. Conclusion: COVID-19 is associated with cardiovascular problems and serious lung damage. ACE2 and TMPRSS2 are key host contributing factors for the severity and pathogenesis of COVID-19. The molecular discoveries into the processes of viral infection and its consequences for cardiovascular disease provide important considerations for the management and treatment of COVID-19-related cardiovascular injury.
- 20 November 2023
- Published by Wiley
Open AccessFUTURE PROGNOSIS FOR CARDIOVASCULAR COMPLICATIONS ASSOCIATED WITH SARS-COV-2: A PHARMACOLOGICAL AND MOLECULAR PERSPECTIVE
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the coronavirus disease 2019 (COVID-19), which is associated with cardiovascular problems and serious lung damage. COVID-19 patients with comorbid conditions are at a significantly elevated risk of increased morbidity and mortality. Angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) are the two key host contributing factors for the severity and pathogenesis of COVID-19. The principal SARS-CoV-2 entrance receptor, ACE2, is expressed equally in most organs and produces cardio-protective vasodilators by physically degrading angiotensin II, the main controller of the Renin-Angiotensin Aldosterone System. However, treatment for cardiovascular disease (CVD) commonly involves RAAS inhibitors, which may increase ACE2 expression. Objective: To summarize the pharmacological molecular discoveries into the processes of viral infection and its consequences for cardiovascular disease and to offer suggestions for the practical management and treatment of COVID-19-related cardiovascular injury. Methods: This review focuses on the important considerations related to the cardiovascular manifestations of COVID-19 and discusses the various mechanisms of COVID-19 that contribute to its molecular and pharmacological presentation of cardiovascular injury. Results: The host-pathogen relationship began with ACE2’s attachment to the S-protein and proceeded with TMPRSS2’s proteolytic cleavage of the viral spike (S)-protein and ACE2. Currently discovered protein-protein interactions explain the uniqueness of SARS-CoV-2 infection. Conclusion: COVID-19 is associated with cardiovascular problems and serious lung damage. ACE2 and TMPRSS2 are key host contributing factors for the severity and pathogenesis of COVID-19. The molecular discoveries into the processes of viral infection and its consequences for cardiovascular disease provide important considerations for the management and treatment of COVID-19-related cardiovascular injury.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
Hippocampal Volume And Type 2 Diabetes Mellitus Without Comorbid Malady
Background: Evidence of type 2 diabetes mellitus (T2DM) associated with hippocampal atrophy is reported by researchers all around the globe. The majority of such studies were conducted among the geriatric and elderly populations with other substantial co-morbid diseases. Hence, the present study aims to evaluate the hippocampal volume of T2DM subjects below 60 years without any concomitant disorders and assess the declarative memory. Materials and Methods: The cross-sectional observational study was conducted among the ethnic population of Manipur. A total of 17 T2DM subjects and 17 healthy controls, who are apparently healthy, matched by age, sex, and comparable education, were enrolled in the study. Magnetic Resonance Imaging (MRI) of high-resolution sagittal structural T1-weighted anatomical sequence was acquired using a three-dimension magnetization-prepared rapid-acquisition gradient echo (MPRAGE). The hippocampus volume was measured using the volBrain Automated MRI Brain Volumetry System. Declarative memory was estimated by the Rey Auditory Verbal Learning Test (RAVLT). Results: No statistically significant differences were found in hippocampal volume, and RAVLT scores between T2DM subjects, and healthy controls group (P > 0.05). Conclusions: The study data indicates that there is no particular hippocampal volume vulnerability in T2DM participants within the ethnic population of Manipur.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
Hippocampal Volume And Type 2 Diabetes Mellitus Without Comorbid Malady
Background: Evidence of type 2 diabetes mellitus (T2DM) associated with hippocampal atrophy is reported by researchers all around the globe. The majority of such studies were conducted among the geriatric and elderly populations with other substantial co-morbid diseases. Hence, the present study aims to evaluate the hippocampal volume of T2DM subjects below 60 years without any concomitant disorders and assess the declarative memory. Materials and Methods: The cross-sectional observational study was conducted among the ethnic population of Manipur. A total of 17 T2DM subjects and 17 healthy controls, who are apparently healthy, matched by age, sex, and comparable education, were enrolled in the study. Magnetic Resonance Imaging (MRI) of high-resolution sagittal structural T1-weighted anatomical sequence was acquired using a three-dimension magnetization-prepared rapid-acquisition gradient echo (MPRAGE). The hippocampus volume was measured using the volBrain Automated MRI Brain Volumetry System. Declarative memory was estimated by the Rey Auditory Verbal Learning Test (RAVLT). Results: No statistically significant differences were found in hippocampal volume, and RAVLT scores between T2DM subjects, and healthy controls group (P > 0.05). Conclusions: The study data indicates that there is no particular hippocampal volume vulnerability in T2DM participants within the ethnic population of Manipur.
- Open Access
- 19 May 2020
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 16 (2) , 125-131
Depression Related Pathophysiologies Relevant in Heart Disease: Insights into the Mechanism Based on Pharmacological Treatments
Depressive symptoms are highly prevalent in patients with cardiac diseases. Co-morbid Depression in cardiac patients causes a significant reduction in health-related quality of life for the patients and inflicts an economic burden on the society. Two types of mechanisms that may explain the link between depression and cardiac diseases are the psychosocial and physiopathological mechanisms. Physiopathological mechanisms are direct biological mechanisms, which include hyperactivity of non-adrenergic and Hypothalamic Pituitary Adrenal Axis (HPA), abnormal platelet activation, endothelial dysfunction, and inflammatory process. Psychosocial factors include behavioral or lifestyle factors like smoking alcoholism and physical inactivity. Pharmacologic and therapeutic interventions are effective at reducing symptoms of depression in patients with cardiac disorders. Among pharmacological treatment, SSRIs seems to be effective for the reduction of depressive symptoms among patients with cardiac disorders because of their good efficacy and minimal cardiovascular side effects. Mechanisms of action of SSRI’s in depressive patients with cardiac disorders are associated with their ability to reduce inflammation, platelet, and endothelial dysfunction. This review focuses on the potential pathophysiological and psychosocial links between cardiac diseases and depression, the treatment options, and the importance of routine screening of depressive symptoms in cardiac settings.
- 19 May 2020
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 16 (2) , 125-131
Open AccessDepression Related Pathophysiologies Relevant in Heart Disease: Insights into the Mechanism Based on Pharmacological Treatments
Depressive symptoms are highly prevalent in patients with cardiac diseases. Co-morbid Depression in cardiac patients causes a significant reduction in health-related quality of life for the patients and inflicts an economic burden on the society. Two types of mechanisms that may explain the link between depression and cardiac diseases are the psychosocial and physiopathological mechanisms. Physiopathological mechanisms are direct biological mechanisms, which include hyperactivity of non-adrenergic and Hypothalamic Pituitary Adrenal Axis (HPA), abnormal platelet activation, endothelial dysfunction, and inflammatory process. Psychosocial factors include behavioral or lifestyle factors like smoking alcoholism and physical inactivity. Pharmacologic and therapeutic interventions are effective at reducing symptoms of depression in patients with cardiac disorders. Among pharmacological treatment, SSRIs seems to be effective for the reduction of depressive symptoms among patients with cardiac disorders because of their good efficacy and minimal cardiovascular side effects. Mechanisms of action of SSRI’s in depressive patients with cardiac disorders are associated with their ability to reduce inflammation, platelet, and endothelial dysfunction. This review focuses on the potential pathophysiological and psychosocial links between cardiac diseases and depression, the treatment options, and the importance of routine screening of depressive symptoms in cardiac settings.
- 13 December 2016
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 35 (1) , 64-70
Platelet activating factor: A potential biomarker in acute coronary syndrome?
Summary: Platelet activating factor (PAF) is a potent pro‐inflammatory negotiator that shows distinct spectrum of biological and pharmacological effects. Importantly, it participates in a wide range of pathophysiological conditions. In cardiovascular system, PAF has been shown to have an important role in platelet and neutrophil aggregation, vascular permeability, microvascular leakage, thrombus formation, leukocyte adhesion to the endothelial cells, and initiation and progression of atherosclerosis. The purpose of this article was to review the PAF, a family of lipids that is associated with the pathology of coronary artery diseases due to their association with leading etiological mechanisms such as inflammation, endothelial dysfunction, oxidative and nitrosative stress, and platelet reactivity. This review further provides information about PAF and its potential role as a key contributor to the pathogenesis of cardiovascular disorders.
- 13 December 2016
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 35 (1) , 64-70
Platelet activating factor: A potential biomarker in acute coronary syndrome?
Summary: Platelet activating factor (PAF) is a potent pro‐inflammatory negotiator that shows distinct spectrum of biological and pharmacological effects. Importantly, it participates in a wide range of pathophysiological conditions. In cardiovascular system, PAF has been shown to have an important role in platelet and neutrophil aggregation, vascular permeability, microvascular leakage, thrombus formation, leukocyte adhesion to the endothelial cells, and initiation and progression of atherosclerosis. The purpose of this article was to review the PAF, a family of lipids that is associated with the pathology of coronary artery diseases due to their association with leading etiological mechanisms such as inflammation, endothelial dysfunction, oxidative and nitrosative stress, and platelet reactivity. This review further provides information about PAF and its potential role as a key contributor to the pathogenesis of cardiovascular disorders.